ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
Copyright: © 2025 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).
ORIGINAL RESEARCH
Blood expression of CD39 and CD73 ectonucleotidases in patients with various forms of metabolic-associated fatty liver disease
About authors
1 Institute of Biology, Karelian Research Centre, Russian Academy of Sciences, Petrozavodsk, Russia
2 Petrozavodsk State University, Petrozavodsk, Russia
Correspondence should be addressed: Galina A. Zhulai
Pushkinskaya, 11, Petrozavodsk, Russia; ur.xednay@111-ilaghz
About paper
Funding: the work was supported by grant No. 25-25-00534 of the Russian Science Foundation and used equipment of the Collective Use Centre of Karelian Research Centre of the Russian Academy of Sciences.
Author contribution: Zhulai GA, Kurbatova IV — study planning, collection, processing and analysis of material, statistical processing, article authoring; Dudanova OP — formation of clinical groups, analysis of clinical data, article editing.
Compliance with ethical standards: the study was approved by the Ethics Committee of the Ministry of Health of the Republic of Karelia and Petrozavodsk State University (Minutes No. 48 of March 10, 2023). All participants signed the voluntary informed consent form and the consent form for personal data processing.
Received: 2025-11-11
Accepted: 2025-12-12
Published online: 2025-12-21
|
Fig. 1. The mRNA levels of ENTPD1 (A) and NT5E (B) in the PBLs of MAFLD patients and healthy donors, Me and interquartile range; the differences are significant according to the Mann-Whitney U test with Bonferroni correction.
Fig. 2. Relative levels of CD39-expressing cells in blood cell populations of patients with MAFLD and healthy donors. Me, interquartile range, minimum and maximum values
Fig. 3. Changes in the content of cells expressing CD39 and CD73 ectonucleotidases after activation in healthy donors (n = 6) and patients with MASH (n = 6). A. The content of CD39+ cells, % of the studied population. B. The content of CD73+ cells, % of the studied population. C. MFI of CD39 expression on activated vs. unactivated cells. D. MFI of CD73 expression on activated vs. unactivated cells. The data are presented as M ± SE, * — significant differences from inactive cells (Wilcoxon T test)
Table 1. Clinical and laboratory characteristics of the study groups
Note: the data are presented as M ± m, median in parentheses; * — significant difference from the control group, # — significant difference from the LS group (Mann– Whitney U–test with Bonferroni correction).
Table 2. Cytokine content and FCK-18 levels in the blood plasma of patients with MAFLD and healthy donors
Note: the data are presented as M ± m, median in parentheses; * — significant difference from the control group, # — significant difference from the LS group (Mann– Whitney U test with Bonferroni correction).
Table 3. Relative and absolute levels of CD39-expressing cells in blood cell populations of patients with MAFLD and healthy donors
Note: the data are given as Me (Q1–Q3). * — significant difference from the control group, # — significant difference from the LS group (Mann–Whitney U test withBonferroni correction). Cell populations were isolated using forward scatter (FSC/FS) and side scatter (SSC/SS).
